Embolization biomaterial reinforced with nanotechnology for an in-situ release of anti-angiogenic agent in the treatment of hyper-vascularized tumors and arteriovenous malformations

Eur J Pharm Biopharm. 2015 Oct:96:396-408. doi: 10.1016/j.ejpb.2015.09.006. Epub 2015 Sep 16.

Abstract

A polymer based material was developed to act as an embolic agent and drug reservoir for the treatment of arteriovenous malformations (AVM) and hyper vascularized solid tumors. The aim was to combine the blocking of blood supply to the target region and the inhibition of the embolization-stimulated angiogenesis. The material is composed of an ethanolic solution of a linear acrylate based copolymer and acrylate calibrated microparticles containing nanospheres loaded with sunitinib, an anti-angiogenic agent. The precipitation of the linear copolymer in aqueous environment after injection through microcatheter results in the formation of an in-situ embolization gel whereas the microparticles serve to increase the cohesive properties of the embolization agent and to form a reservoir from which the sunitinib-loaded nanospheres are released post-embolization. The swollen state of the microparticles in contact with aqueous medium results in the release of the nanospheres out of microparticles macromolecular structure. After the synthesis, the formulation and the characterization of the different components of the material, anti-angiogenic activity was evaluated in vitro using endothelial cells and in vivo using corneal neovascularization model in rabbit. The efficiency of the arterial embolization was tested in vivo in a sheep model. Results proved the feasibility of this new system for vascular embolization in association with an in situ delivery of anti-angiogenic drug. This combination is a promising strategy for the management of arteriovenous malformations and solid tumors.

Keywords: Anti-angiogenic; Arteriovenous malformation; Embolization; Gelling solution; Sunitinib.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acrylates / adverse effects
  • Acrylates / chemistry
  • Angiogenesis Inhibitors / administration & dosage*
  • Angiogenesis Inhibitors / adverse effects
  • Angiogenesis Inhibitors / pharmacology
  • Angiogenesis Inhibitors / therapeutic use
  • Animals
  • Arteriovenous Malformations / drug therapy
  • Biocompatible Materials / adverse effects
  • Biocompatible Materials / chemistry
  • Cell Proliferation / drug effects
  • Cells, Cultured
  • Cornea / blood supply
  • Cornea / drug effects
  • Cornea / pathology
  • Delayed-Action Preparations / administration & dosage
  • Delayed-Action Preparations / adverse effects
  • Delayed-Action Preparations / pharmacology
  • Delayed-Action Preparations / therapeutic use
  • Drug Compounding
  • Drug Delivery Systems* / adverse effects
  • Embolization, Therapeutic* / adverse effects
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / pathology
  • Gels
  • Human Umbilical Vein Endothelial Cells / cytology
  • Indoles / administration & dosage*
  • Indoles / adverse effects
  • Indoles / pharmacology
  • Indoles / therapeutic use
  • Intercostal Muscles / blood supply
  • Intercostal Muscles / drug effects
  • Intercostal Muscles / pathology
  • Nanospheres / adverse effects
  • Nanospheres / chemistry*
  • Neovascularization, Pathologic / pathology
  • Neovascularization, Pathologic / prevention & control*
  • Pyrroles / administration & dosage*
  • Pyrroles / adverse effects
  • Pyrroles / pharmacology
  • Pyrroles / therapeutic use
  • Rabbits
  • Random Allocation
  • Sheep, Domestic
  • Sunitinib

Substances

  • Acrylates
  • Angiogenesis Inhibitors
  • Biocompatible Materials
  • Delayed-Action Preparations
  • Gels
  • Indoles
  • Pyrroles
  • Sunitinib